Group items tagged

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.

Believe it or not, light can make you obese. In a study, Japanese researchers found that in case older people are exposed to dim light in morning and bright light in evening then chances are they will gain weight. They will end up losing weight in case the light intensities are reversed, researchers say.

Japanese researchers at Okayama University have found that paternal high-fat diet (HFD) intake may lead to a number of changes in next generations including generational obesity and metabolic dysfunction. But, if the next two generations are given controlled diet, the metabolic effects of grand paternal high-fat diet may be diminished.

Scottish biotechnology firm TC BioPharm (TCB) and Japanese immuno-cell therapy company Medinet have entered into a strategic collaboration to develop a new treatment for different types of cancer.

Havoc, the steroid is the methylated derivative of Japanese anti-estrogenic steroid, thioderon. The drug can be administered orally since it directly passes through the liver onto the blood stream due to the chemical composition. It generates genuine steroidal results and is sold as the prescription drug.

https://www.mymedistore.com/product/cimivir-400-mg/ Buy Cimivir 400 mg Online - Order Cheapest Cimivir 400 mg from Mymedistore- your most reliable online pharmacy. Avail best price in USA, by your doorsteps.

harg cytotec 18plusmed : 085740559466. Memperkenalkan Obat Cytotec di Depok yang aman dan 100% ampuh dalam menggugurkan Janin hingga beres dan tuntas sampai bersih.

MD Anderson Cancer Center and Ascentage Pharma entered into a five-year collaboration that aims to accelerate clinical development of novel apoptosis-targeted and tyrosine kinase inhibitor drug candidates for leukemia treatment. Read the complete report Click on http://bit.ly/2NIzta5